

24 November 2015 EMA/HMPC/436679/2015 Committee on Herbal Medicinal Products (HMPC)

European Union herbal monograph on *Althaea officinalis* L., radix

Draft - revision

| Discussion in Working Party on European Union monographs and | March 2008 |
|---|------------------|
| European Union list (MLWP) | May 2008 |
| | July 2008 |
| | January 2009 |
| Adoption by Committee on Herbal Medicinal Products (HMPC) for | 17 July 2008 |
| release for consultation | |
| End of consultation | 15 November 2008 |
| Re-discussion in MLWP | January 2009 |
| | March 2009 |
| Adoption by HMPC | 14 May 2009 |
| Monograph (EMEA/HMPC/98717/2008) | |
| AR (EMEA/HMPC/98718/2008) | |
| List of references (EMEA/HMPC/98716/2008) | |
| Overview of comments received during the public | |
| consultation (EMEA/HMPC/2920/2009) | |
| HMPC Opinion (EMEA/HMPC/109223/2009) | |
| First systematic review | |
| Discussion in MLWP | July 2015 |
| | September 2015 |
| Adoption by HMPC | 24 November 2015 |
| Start of public consultation | 11 December 2015 |
| End of consultation (deadline for comments). Comments should be | 15 March 2016 |
| provided using this template to hmpc.secretariat@ema.europa.eu | |

| Keywords | Herbal medicinal products; HMPC; European Union herbal monographs; | |
|----------|--|--|
| | traditional use; Althaea officinalis L., radix; Althaeae radix; Marshmallow root | |



BG (bulgarski): Лечебна ружа, корен CS (čeština): proskurníkový kořen

DA (dansk): Altæarod

DE (Deutsch): Eibischwurzel

EL (elliniká): ρίζα αλταίας- ρίζα αλθαίας

EN (English): Marshmallow root ES (español): Altea, raíz de ET (eesti keel): alteejuur

FI (suomi): rohtosalkoruusu, juuri FR (français): Guimauve (racine de)

HR (hrvatski): korijen običnog bijelog sljeza

HU (magyar): orvosi ziliz gyökér

IT (italiano): Altea radice

LT (lietuvių kalba): Svilarožių šaknys LV (latviešu valoda): Altejas saknes MT (Malti): Għerq tal-Ħobbejża Mediċinali

NL (Nederlands): Echte Heemst

PL (polski): Korzeń prawoślazu PT (português): Alteia, raiz

RO (română): rădăcină de nalbă mare

SK (slovenčina): Koreň ibiša

SL (slovenščina): korenina navadnega sleza

SV (svenska): Läkemalva, rot

IS (íslenska):

NO (norsk): Altearot

European Union herbal monograph on *Althaea officinalis* L., radix

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition^{1, 2}

| Well-established use | Traditional use |
|----------------------|--|
| | With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended |
| | Althaea officinalis L., radix (Marshmallow root) |
| | i) Herbal substance |
| | Not applicable. |
| | ii) Herbal preparations |
| | a) Comminuted herbal substance |
| | b) Liquid extract (DER 1:19.5-23.5), extraction solvent water |
| | c) Macerate for preparation of syrup ³ |
| | d) Dry extract (DER 3-9:1), extraction solvent water |
| | e) Liquid extract (DER 1:1), extraction solvent ethanol 25% (V/V) |

3. Pharmaceutical form

| Well-established use | Traditional use |
|----------------------|--|
| | Comminuted herbal substance as herbal tea for oral use. Herbal preparations in liquid or solid dosage forms for oral or oromucosal use. |
| | The pharmaceutical form should be described by |

¹ The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

 $^{^{2}}$ The material complies with the Ph. Eur. monograph (ref.: 1126)

³ Prepared in accordance with the pharmacopoeial monographs for Sirupus althaeae in Österreichisches Arzneibuch 1981, Československý lékopis1954, Farmakopea Polska 1970 and 2002 or with the monograph Eibischsirup in Deutscher Arzneimittel-Codex 1979

| Well-established use | Traditional use |
|----------------------|--|
| | the European Pharmacopoeia full standard term. |

4. Clinical particulars

4.1. Therapeutic indications

| Well-established use | Traditional use |
|----------------------|---|
| | Indication 1 |
| | Traditional herbal medicinal product used as a demulcent preparation for the symptomatic treatment of oral or pharyngeal irritation and associated dry cough. |
| | Indication 2 |
| | Traditional herbal medicinal product used as a demulcent preparation for the symptomatic relief of mild gastrointestinal discomfort. |
| | The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use. |

4.2. Posology and method of administration⁴

| Well-established use | Traditional use |
|----------------------|--|
| | Posology |
| | Oral use |
| | a) Comminuted herbal substance |
| | Indication 1) |
| | Adolescents, adults and elderly |
| | Herbal tea: 0.5 - 3 g of the comminuted herbal substance in 150 ml of water as a macerate several times daily Maximum daily dose: 15 g |
| | Children 6-12 years of age |
| | Herbal tea: 0.5 – 1.5 g of the comminuted herbal substance in 150 ml of water as a macerate 3 times daily Daily dose: 1.5 – 4.5 g |

⁴ For guidance on herbal substance/herbal preparation administered as herbal tea or as infusion/decoction/macerate preparation, please refer to the HMPC 'Glossary on herbal teas' (EMA/HMPC/5829/2010 Rev.1).

| Well-established use | Traditional use |
|----------------------|---|
| | Children 3-5 years of age |
| | Herbal tea: 0.5 – 1.0 g of the comminuted herbal substance in 150 ml of water as a macerate 3 times daily Daily dose: 1.5 – 3.0 g |
| | The use in children under 3 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). |
| | Indication 2) |
| | Adolescents, adults and elderly |
| | Herbal tea: 3 - 5 g of the comminuted herbal substance in 150 ml of water as a macerate 3 times daily Maximum daily dose: 15 g |
| | The use in children under 12 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). |
| | b) Liquid extract (DER 1:19.5-23.5) |
| | Indication 1) |
| | Adolescents, adults and elderly |
| | Single dose: 4.6 g 3 – 6 times daily Daily dose: 13.8 – 27.6 g |
| | Children 6-12 years of age |
| | Single dose: 2.3 g 5 times daily Daily dose: 11.5 g |
| | Children 3-5 years of age |
| | Single dose: 1.9 g 4 times daily Daily dose: 7.6 g |
| | The use in children under 3 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). |
| | c) Macerate for preparation of syrup |
| | Indication 1) |
| | Adolescents, adults and elderly |
| | Single dose: macerate amount corresponding to 0.21 to 0.87 g of the herbal substance (10 – 15 ml of syrup) 3 – 5 times daily |

| Well-established use | Traditional use |
|----------------------|---|
| | Daily dose: macerate amount corresponding to 0.63 to 2.9 g of the herbal substance (30 – 50 ml of syrup) |
| | Children 6-12 years of age |
| | Single dose: macerate amount corresponding to 0.1 to 0.29 g of the herbal substance (5 ml of syrup) 3 - 5 times daily Daily dose: macerate amount corresponding to 0.32 to 1.45 g of the herbal substance (15 - 25 ml of syrup) |
| | Children 3-5 years of age |
| | Single dose: macerate amount corresponding to 0.1 to 0.29 g of the herbal substance (5 ml of syrup) up to 4 times daily Daily dose: macerate amount corresponding to 0.21 to 1.16 g of herbal substance (10 – 20 ml of syrup) |
| | The use in children under 3 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). |
| | e) Liquid extract (DER 1:1) |
| | Indication 1) and 2) |
| | Adults and elderly |
| | Single dose: 2 – 5 ml 3 times daily Daily dose: 6 – 15 ml |
| | The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). |
| | Oromucosal use |
| | d) Dry extract (DER 3-9:1) |
| | Indication 1) |
| | Adolescents, adults and elderly |
| | Single dose: 160 mg several times daily Maximum daily dose: 1.6 g |
| | Children 6-12 years of age |
| | Single dose: 160 mg 3 times daily |

| Well-established use | Traditional use |
|----------------------|---|
| | Daily dose: 480 mg |
| | The use in children under 6 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). |
| | Duration of use |
| | Indication 1) If the symptoms persist longer than 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Indication 2) If the symptoms persist longer than 2 weeks during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. |
| | Method of administration |
| | Preparations a) b), c) and e) Oral use. |
| | Preparation d) |
| | Oromucosal use. |
| | The macerate should be used immediately after preparation. |

4.3. Contraindications

| Well-established use | Traditional use |
|----------------------|---|
| | Hypersensitivity to the active substance. |

4.4. Special warnings and precautions for use

| Well-established use | Traditional use |
|----------------------|---|
| | Indication 1) |
| | If dyspnoea, fever or purulent sputum occurs during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. |
| | Preparations a), b) and c) |
| | The use in children under 3 years of age is not |
| | recommended because of concerns requiring |

| Well-established use | Traditional use |
|----------------------|--|
| | medical advice. |
| | Preparation d) |
| | The use in children under 6 years of age is not recommended because of the pharmaceutical form (solid dosage form). |
| | Preparation e) |
| | The use in children and adolescents under 18 years of age has not been established due to lack of adequate data. |
| | For syrup the appropriate labelling for sucrose, taken from the 'Guideline on excipients in the label and package leaflet of medicinal products for human use', must be included. |
| | Indication 2) |
| | Preparation a) |
| | The use in children under 12 years of age has not been established due to lack of adequate data. |
| | Preparation e) |
| | The use in children and adolescents under 18 years of age has not been established due to lack of adequate data. |
| | Indications 1) and 2) |
| | Absorption of concomitantly administered medicines may be delayed. As a precautionary measure, the product should not be taken ½ to 1 hour before or after intake of other medicinal products. |
| | If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. |
| | For extracts containing ethanol, the appropriate labelling for ethanol, taken from the 'Guideline on excipients in the label and package leaflet of medicinal products for human use', must be included. |

4.5. Interactions with other medicinal products and other forms of interaction

| Well-established use | Traditional use |
|----------------------|-----------------|
| | None reported. |

4.6. Fertility, pregnancy and lactation

| Well-established use | Traditional use |
|----------------------|---|
| | Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. |
| | No fertility data available. |

4.7. Effects on ability to drive and use machines

| Well-established use | Traditional use |
|----------------------|--|
| | No studies on the effect on the ability to drive and use machines have been performed. |

4.8. Undesirable effects

| Well-established use | Traditional use |
|----------------------|---|
| | None known. |
| | If adverse reactions occur, a doctor or a qualified health care practitioner should be consulted. |

4.9. Overdose

| Well-established use | Traditional use |
|----------------------|--|
| | No case of overdose has been reported. |

5. Pharmacological properties

5.1. Pharmacodynamic properties

| Well-established use | Traditional use |
|----------------------|--|
| | Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended. |

5.2. Pharmacokinetic properties

| Well-established use | Traditional use |
|----------------------|--|
| | Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended. |

5.3. Preclinical safety data

| Well-established use | Traditional use |
|----------------------|--|
| | Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product. |
| | Adequate tests on genotoxicity have not been performed. |
| | Tests on reproductive toxicity and carcinogenicity have not been performed. |

6. Pharmaceutical particulars

| Well-established use | Traditional use |
|----------------------|-----------------|
| | Not applicable. |

7. Date of compilation/last revision

24 November 2015